Lonza said it is planning to pump almost $1 billion to expand manufacturing capabilities in the U.S. and Switzerland.
Under the new plans, the CDMO will grow its mammalian drug-substance manufacturing prowess with a new, large-scale plant in Visp, Switzerland complete with six 20,000L bioreactors in about 27,500 square-meters. The plant is slated for completion in 2024.
The company also plans to build a 3,000-square meter plant in New Hampshire with up to eight 2,000L bioreactors that it plans to finish by 2023.
All told, the company will invest $935 million into the expansion plans will create about 550 jobs across the two sites.
Lonza also recently announced a plan to expand its drug substance manufacturing in Visp to support vaccine production for Moderna’s vaccine. The new 10-year agreement will add three production lines in Visp.